Viravaxx

Meet us at

Viravaxx will be presenting data from an interim analysis of its Hepatitis B therapeutic vaccine candidate VVX001 at the following upcoming conferences:

  • AASLD (American Association for the Study of Liver Diseases), November 12-15, 2021, Anaheim, California, USA: AASLD 2021
  • HEP DART (Frontiers in Drug Development for Hepatology), December 5-9, 2021, Cabo San Lucas, Mexico: HEP DART 2021

Viravaxx will be represented by its Principal Investigator, Prof. Dr. Petra Munda, and its key Hepatitis B scientific advisor, Prof. Dr. Peter Ferenci, both from MedUni Vienna.